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Various 4-bromomethylcoumarins (1a-k) were reacted with methyl salicylate to yield 2-(2-oxo-2H-chromen-4-ylmethoxy)-
benzoic acid methyl esters (2a-k). Formations of (3a-k) were achieved by using DBU under microwave irradiation. Structures of all
the compounds were established on the basis of their spectral data. All the compounds were tested in vitro for their antimicrobial
activity and cell cytotoxicity. All the tested compounds (2b-k) and (3a-k) were shown to be better activity against Staphylococcus
aureus than the standard Ciprofloxacin. The compound (3k) (R = 6-OMe) was found to be more potent cytotoxic than the standard
5-fluorouracil.
1. Introduction
Benzofuran and its derivatives [1] have attracted consid-
erable interest in recent years for their versatile proper-
ties in chemistry and pharmacology. 3-Benzofuran-5-aryl-
1-pyrazolylcarbonyl-4-oxo-naphthyridin [2] was found to
be the most potent antitubercular agent against Mycobac-
terium tuberculosis, even better than standard drug isoniazid.
Benzofuran derivatives [3] were found to exhibit favorable
antibacterial activity against Staphylococcus aureus and Bacil-
lus subtilis which were better than the control drugs Cefo-
taxime and Ketoconazole. 2-Phenylbenzofurans [4] exhibited
enhanced antiprotozoal activity against Trypanosoma brucei
rhodesiense and Plasmodium falciparum. 2-Arylbenzofurans
[5] were isolated from the roots ofGlycyrrhiza uralensis.They
showed significant in vitro protein tyrosine phosphate-1B
inhibitory activity. Technetium-99m labeled pyridyl benzofu-
ran derivatives [6] was tested as potential probes for imaging
𝛽-amyloid plaques in Alzheimer’s brains using single photon
emission computed tomography.
Coumarin moieties are widely featured in a broad range
of pharmacological and biologically active compounds [7,
8]. Phosphorohydrazine derivatives of coumarin displayed
high in vivo antitumour activity against P388 leukemia [9].
Coumarin pyrazoline hybridswere found to possess the high-
est cytotoxicity against colorectal cell line HCT-116 with IC
50
value of 0.01𝜇M [10].Thiazolyl coumarin derivatives showed
significant inhibition against Haemophilus influenzae with a
MIC value of 15 𝜇M which is less than that of tetracycline
[11]. Benzo[d]thiazolyl coumarins [12] demonstrated anti-
HIV activity against HIV-1 cell with EC
50
< 7 𝜇g/mL.
Based on the survey of recent literature studies on
coumarins and benzofurans and in our effort to discover
novel antimicrobial [13–16] and anticancer agents [17, 18], the
aim of our work is synthesis of 4-(3-hydroxy-benzofuran-2-
yl)coumarins and the evaluation of them for their therapeutic
importance.
2. Chemistry
The synthetic scheme for the target molecules was
initiated by the Pechmann cyclisation of phenols with
4-bromoethylacetoacetate [19] leading to the required
4-bromomethylcoumarins [20–22] (1a-k). The compound 4-
(6-methyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
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methyl ester [23] (2a) (R = 6-CH
3
) was synthesized by
reacting 4-bromomethyl-6-methylcoumarin and methyl
salicylate in the presence of anhydrous K
2
CO
3
. Using this
method, the compounds (2b-k) were synthesized. These
intermediates (2a-k) did not yield the products (3a-k) in
the presence of DBU in DMF under thermal conditions.
However, when subjected to microwave irradiation afforded
the compounds (3a-k) (Scheme 1). The completion of the
reaction is monitored by TLC. A plausible mechanistic
pathway proposed for the title compounds involves the
generation of a carbanion at the active methylene group
(C
4
–CH
2
) which is stabilized by coumarin ring [24]. The
intramolecular ring closure occurred when carbanion
attacked the carbonyl carbon of methyl ester and eliminated
methanol to form 4-(3-oxo-2,3-dihydro-benzofuran-2-yl)-
coumarins that underwent in situ aromatization under the
reaction conditions to yield 4-(3-hydroxy-benzofuran-2-yl)-
coumarins (Figure 1). The high melting solids separated in
the reaction mixture were filtered off to obtain compounds
(3a-k) as crystalline solids.
3. Results and Discussion
The structures of novel (2-oxo-2H-chromen-4-ylmethoxy)-
benzoic acid methyl esters and 4-(3-hydroxy-benzofuran-2-
yl)-coumarins were established from IR, 1HNMR, 13CNMR,
and LC-MS data as illustrated for a representative example.
In the IR spectrum of 2-(7-methyl-2-oxo-2H-chromen-4-
ylmethoxy)-benzoic acid methyl ester (2b) (R = 7-CH
3
),
the lactone carbonyl stretching frequency was appeared at
1720 cm−1, whereas the methyl ester carbonyl stretching
frequency was observed at 1742 cm−1.The 1HNMR spectrum
of the compound (2b) displayed a singlet at 𝛿 2.40, 3.85,
5.52, and 6.85 due to CH
3
, OCH
3
, OCH
2,
and C
3
–H protons,
respectively. The aromatic protons resonated as a multiplet at
𝛿 7.10–7.83.
The IR spectrum of the compound 4-(3-hydroxy-
benzofuran-2-yl)-6-methylcoumarin (3a) (R = 6-CH
3
)
displayed a lactone carbonyl stretching frequency at
1729 cm−1, whereas the –OH stretching frequency appeared
at 3450 cm−1. The 1H NMR spectrum of the compound (3a)
showed a singlet at 𝛿 2.42 and 6.93 due to CH
3
and C
3
–H
protons, respectively. The aromatic protons were resonated
as a multiplet at 𝛿 7.23–8.48. The –OH proton observed as a
singlet at 𝛿 11.42 that was confirmed by D
2
O exchange. The
mass spectrum (LC-MS) of the compound (3g) displayed a
[M+H] peak at 307.The 13CNMR spectral data of compound
(3h) are given in the experimental section.
4. Antimicrobial Activity
All the newly synthesized compounds (2b-k) and (3a-k)
were screened for their antibacterial and antifungal activity
at different concentrations of 100, 50, 25, 12.5, 6.25, 3.125,
1.6, 0.8, and 0.2 𝜇g/mL via broth microdilution method. The
minimum inhibitory concentrations (MIC) were determined
by serial dilution method [25].
Antibacterial activity was carried out against three Gram-
positive bacteria, namely, Staphylococcus aureus, Enterococcus
faecalis, and Streptococcus mutans, and three Gram-negative
bacteria, namely, Escherichia coli, Klebsiella pneumonia, and
Pseudomonas aeruginosa. Ciprofloxacin was used as a stan-
dard. Antifungal activity was carried out against two fungi,
namely,Candida albicans andAspergillus fumigatus. Flucona-
zole was used as a standard.
The investigation of antimicrobial screening data
(Table 1) showed thatmost of the tested compounds exhibited
good bacterial and fungal inhibition. The compounds (2b)
(R = 7-CH
3
), (2c) (R = 6-Cl), (2e) (R = 6-F), and (2f) (R =
5,6-benzo) were found to be very active against S. mutans
with MIC of 0.2 𝜇g/mL. The compounds (2c) (R = 6-Cl)
and (2i) (R = 6-tert-butyl) were found to be highly active
against E. coli with MIC of 0.2 𝜇g/mL.The compound (2i) (R
= 6-tert-butyl) displayed high activity against A. fumigatus
with MIC of 0.2 𝜇g/mL. The compounds (3a) (R = 6-CH
3
)
and (3b) (R = 7-CH
3
) were found to be highly active against
S. aureus, E. faecalis, and S. mutans with MIC of 0.2 𝜇g/mL.
The compounds (3e) (R = 6-F) and (3f) (R = 5,6-benzo)
were found to be highly active against S. aureus and C.
albicans with MIC of 0.2 𝜇g/mL. The compounds (3g) (R =
6,8-dimethyl), (3h) (R = 6-isopropyl), (3i) (R = 6-tert-butyl),
and (3j) (R = 6-benzyl) exhibited high activity against S.
aureus, S. mutans, and C. albicans with MIC of 0.2 𝜇g/mL.
The compound (3k) (R = OMe) showed high activity
against S. aureus and C. albicans with MIC of 0.2 𝜇g/mL.
It is to be noted that most of these compounds exhibited
moderate activity against P. aeruginosa and inactive against
K. pneumonia.
In general, uncyclized compounds (2b-k) aremore potent
than the cyclized compounds (3a-k) against S. mutans and
E. coli. The cyclized compounds (3a-k) are more potent
than the uncyclized compounds (2b-k) against E. faecalis
and C. albicans. It is interesting to found that both cyclized
and uncyclized compounds showed better activity against S.
aureus than the standard Ciprofloxacin.
5. In Vitro Cell Cytotoxicity
All the newly synthesized compounds (2b-k) and (3a-k)
were evaluated for their cytotoxicity against DAL cell using
trypan blue dye exclusion assay. The detail procedure has
been described in our earlier publications [26, 27].
The investigation of in vitro cell cytotoxicity (Table 2)
revealed that most of the tested compounds exhibited good
activity. The compounds (2d) (R = 6-Br), (2h) (R = 6-
isopropyl), (2i) (R = 6-tert-butyl), (2j) (R = 6-benzyl), (2k)
(R = 6-OMe), (3a) (R = 6-CH
3
), (3c) (R = 6-Cl), (3f)
(R = 5,6-benzo), (3g) (R = 6,8-dimethyl), (3h) (R = 6-
isopropyl), (3i) (R = 6-tert-butyl), and (3k) (R = 6-OMe)
were found to be highly active (>70%) against DAL cell at
the concentration of 100 𝜇g/mL.The compound (2f) (R = 5,6-
benzo) was found to be poor active (25%) against DAL cell at
the concentration of 100 𝜇g/mL. The rest of the compounds
were found to be moderately active (>40%). In general, the
cyclized compounds (3a-k) were found to be more potent
than the uncyclized compounds (2b-k).
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Figure 1: Plausible mechanism for the synthesis of (3a-k).
6. Experimental Section
The melting points were measured with an electric melting
point apparatus and are uncorrected. The IR spectra were
obtained using a Shimadzu-8400S FT-IR spectrophotometer.
1H NMR and 13C NMR spectra in DMSO-𝑑
6
solution were
recorded at 25∘Con a Bruker 300 and 400MHz spectrometer,
respectively. The 1H chemical shifts were reported in 𝛿 ppm
and referenced toTMS.Themass spectrawere recorded on an
Agilent-Single Quartz LC-MS. The purity of the compounds
was checked by TLC. Microwave reactions were carried out
on Milestone Laboratory’s microwave reactor. The elemental
analyses were carried out using Elemental Vario Micro Cube
CHNS Rapid Analyzer. All the compounds gave satisfactory
elemental analysis.
General Procedure for the Synthesis of Compounds (2a-k).
Methyl salicylate (0.304 g, 2.0mmol) and anhydrous K
2
CO
3
(1.38 g, 10mmol) were stirred in 25mL of dry acetone
for 30min. 4-Bromomethylcoumarin (1a-k) (2.0mmol) was
added and stirring was continued for 24 h. The reaction
mixture was concentrated to one-fourth volume and poured
onto crushed ice.The solid separated was filtered and washed
with 10mL of 5%HCl.Then, it was washedwith 50mL of cold
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Table 1: Results of antimicrobial activities of the synthesized compounds (2b–k) and (3a–k) MICs (𝜇g/mL).
Compounds Gram-positive Gram-negative Fungi
Number R S. aureus E. faecalis S. mutans E. coli K. pneumonia P. aeruginosa C. albicans A. fumigatus
2b 7-CH3 0.4 50 0.2 6.25 100 6.25 12.5 0.4
2c 6-Cl 0.4 1.6 0.2 0.2 50 3.12 12.5 0.4
2d 6-Br 0.8 25 0.4 1.6 100 3.12 12.5 0.4
2e 6-F 0.4 3.12 0.2 1.6 100 6.25 >100 0.8
2f 5,6-benzo 0.4 50 0.2 6.25 100 6.25 12.5 0.4
2g 6,8-dimethyl 1.6 0.8 0.8 3.12 100 50 100 1.6
2h 6-isopropyl 0.8 6.25 0.4 0.4 100 25 12.5 0.4
2i 6-tert-butyl 0.8 6.25 0.8 0.2 100 25 12.5 0.2
2j 6-benzyl 0.8 12.5 0.4 1.6 100 6.25 100 0.8
2k 6-OMe 0.8 3.12 0.8 3.12 100 100 100 0.8
3a 6-CH3 0.2 0.2 0.2 50 100 50 12.5 —
3b 7-CH3 0.2 0.2 0.2 100 50 >100 0.2 —
3c 6-Cl 0.2 0.4 0.2 100 100 25 3.12 —
3d 6-Br — — — — — — — —
3e 6-F 0.2 0.4 0.4 100 100 >100 0.2 —
3f 5,6-benzo 0.2 0.4 3.12 50 100 0.2 0.2 —
3g 6,8-dimethyl 0.2 0.4 0.2 100 100 50 0.2 —
3h 6-isopropyl 0.2 0.4 0.2 50 100 3.12 0.2 —
3i 6-tert-butyl 0.2 0.8 0.2 50 >100 6.25 0.2 —
3j 6-benzyl 0.2 0.8 0.2 100 100 50 0.2 —
3k 6-OMe 0.2 0.4 3.12 50 100 6.25 0.2 —
Ciprofloxacin 2 2 2 1 1 4 — —
Fluconazole — — — — — — 16 8
water. The crude product was dried and recrystallised from
ethanol.
2-(7-Methyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2b). Yield 90%; colorless solid; mp. 168–170∘C;
IR (KBr, cm−1): 1720 (lactone C=O), 1742 (methyl ester,
C=O); 1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 2.40 (s, 3H, CH
3
),
3.85 (s, 3H, OCH
3
), 5.52 (s, 2H, OCH
2
), 6.85 (s, 1H, C
3
–H),
7.10–7.83 (m, 7H, Ar–H) ppm; Anal. Cald. for C
19
H
16
O
5
: C,
70.36; H, 4.97. Found: C, 70.27; H, 4.89.
2-(6-Chloro-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2c). Yield 92%; colorless solid; mp. 188–191∘C; IR
(KBr, cm−1): 1730 (lactone C=O), 1750 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.81 (s, 3H, OCH
3
),
5.46 (s, 2H, OCH
2
), 6.90 (s, 1H, C
3
–H), 7.07–8.04 (m, 7H,
Ar–H) ppm; Anal. Cald. for C
18
H
13
ClO
5
: C, 62.71; H, 3.80.
Found: C, 62.65; H, 3.73.
2-(6-Bromo-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2d). Yield 89%; yellow solid; mp. 147–149∘C; IR
(KBr, cm−1): 1714 (lactone C=O), 1750 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.85 (s, 3H, OCH
3
),
5.49 (s, 2H, OCH
2
), 6.79 (s, 1H, C
3
–H), 7.12–7.82 (m, 7H,
Ar–H) ppm; Anal. Cald. for C
18
H
13
BrO
5
: C, 55.55; H, 3.37.
Found: C, 55.48; H, 3.32.
2-(6-Fluoro-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2e). Yield 90%; colorless solid; mp. 186–149∘C;
IR (KBr, cm−1): 1724 (lactone C=O), 1739 (methyl ester
C=O); 1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.86 (s, 3H,
OCH
3
), 5.50 (s, 2H, OCH
2
), 6.92 (s, 1H, C
3
–H), 7.10–8.12
(m, 7H, Ar–H) ppm; Anal. Cald. for C
19
H
15
FO
4
: C, 69.93; H,
4.63. Found: C, 69.86; H, 4.58.
2-(5,6-Benzo-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2f ). Yield 90%; light yellow solid; mp. 183–
186∘C; IR (KBr, cm−1): 1728 (lactone C=O), 1746 (methyl
ester C=O); 1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.83 (s, 3H,
OCH
3
), 5.95 (s, 2H, OCH
2
), 7.12–8.42 (m, 11H, Ar–H) ppm;
Anal. Cald. for C
22
H
16
O
5
: C, 73.33; H, 4.48. Found: C, 73.26;
H, 4.40.
2-(6,8-Dimethyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic
acid methyl ester (2g). Yield 91%; colorless solid; mp. 193–
195∘C; IR (KBr, cm−1): 1727 (lactone C=O), 1739 (methyl
ester C=O); 1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 2.36 (d, 6H,
6,8-dimethyl), 3.85 (s, 3H, OCH
3
), 5.47 (s, 2H, OCH
2
), 6.84
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Table 2: Results of in vitro cytotoxicity of the synthesized compounds (2b–k) and (3a–k) against Dalton’s Ascitic Lymphoma cell (1 × 105)
at the concentration of 100 𝜇g/mL.
Number of compounds R Number of cells % of dead cells
Live Dead
2b 7-CH3 49 51 51
2c 6-Cl 41 59 59
2d 6-Br 19 81 81
2e 6-F 42 58 58
2f 5,6-benzo 75 25 25
2g 6,8-dimethyl 55 45 45
2h 6-isopropyl 12 88 88
2i 6-tert-butyl 16 84 84
2j 6-benzyl 13 87 87
2k 6-OMe 18 82 82
3a 6-CH3 21 79 79
3b 7-CH3 56 44 44
3c 6-Cl 15 85 85
3d 6-Br — — —
3e 6-F 34 66 66
3f 5,6-benzo 13 87 87
3g 6,8-dimethyl 21 79 79
3h 6-isopropyl 26 74 74
3i 6-tert-butyl 15 85 85
3j 6-benzyl 53 47 47
3k 6-OMe 11 89 89
5-Fluorouracil — 12 88 88
(s, 1H, C
3
–H), 7.08–7.82 (m, 6H, Ar–H) ppm; Anal. Cald. for
C
22
H
22
O
5
: C, 71.10; H, 5.36. Found: C, 71.03; H, 5.29.
2-(6-Isopropyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2h). Yield 97%; colorless solid; mp. 179–182∘C;
IR (KBr, cm−1): 1718 (lactone C=O), 1746 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 1.27 (d, 6H, 2-CH
3
of
isopropyl), 3.02 (m, 1H, CHof isopropyl), 3.88 (s, 3H, OCH
3
),
5.55 (s, 2H, OCH
2
), 6.88 (s, 1H, C
3
–H), 7.10–7.87 (m, 7H, Ar–
H) ppm; Anal. Cald. for C
21
H
20
O
5
: C, 71.58; H, 5.72. Found:
C, 71.50; H, 5.66.
2-(6-Tert-butyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2i). Yield 89%; colorless solid; mp. 172–173∘C;
IR (KBr, cm−1): 1716 (lactone C=O), 1728 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 1.37 (s, 9H, 6-tert-butyl),
3.81 (s, 3H, OCH
3
), 5.53 (s, 2H, OCH
2
), 6.93 (s, 1H, C
3
–H)
7.23–7.91 (m, 7H, Ar–H) ppm; Anal. Cald. for C
21
H
20
O
5
: C,
72.00; H, 6.05. Found: C, 71.83; H, 5.97.
2-(6-Benzyl-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2j). Yield 89%; colorless solid; mp. 172–175∘C;
IR (KBr, cm−1): 1712 (lactone C=O), 1738 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.84 (s, 3H, OCH
3
), 4.03
(s, 2H, C
6
–CH
2
), 5.51 (s, 2H, OCH
2
), 6.86 (s, 1H, C
3
–H),
7.10–7.89 (m, 12H, Ar–H) ppm; Anal. Cald. for C
25
H
20
O
5
: C,
74.99; H, 5.03. Found: C, 74.91; H, 4.95.
2-(6-Methoxy-2-oxo-2H-chromen-4-ylmethoxy)-benzoic acid
methyl ester (2k). Yield 95%; colorless solid; mp. 174–176∘C;
IR (KBr, cm−1): 1720 (lactone C=O), 1739 (methyl ester C=O);
1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 3.85 (d, 6H, 6-OCH
3
,
OCH
3
), 5.52 (s, 2H, OCH
2
), 6.84 (s, 1H, C
3
–H), 7.13–7.82 (m,
7H, Ar–H) ppm; Anal. Cald. for C
19
H
16
O
6
: C, 67.05; H, 4.74.
Found: C, 66.97; H, 4.67.
General Procedure for the Synthesis of Compounds (3a-k).
A mixture of 2-(2-oxo-2H-chromen-4-ylmethoxy)-benzoic
acid methyl ester (2a-k) (2.0mmol), DBU (0.3 g, 2.0mmol)
and DMF (25mL) were added to a microwave tube equipped
with a magnetic stir bar. The microwave tube was fitted with
a reflux condenser and irradiated in a microwave reactor at
a temperature of 140∘C for 4min at a maximum power of
370W.Then, completion of the reaction mixture was poured
onto ice cold water and neutralizedwith dil HCl solution.The
solid separated was filtered and washed with 100mL of cold
water. The crude product was dried and recrystallised from
ethanol.
4-(3-Hydroxy-benzofuran-2-yl)-6-methyl-chromen-2-one (3a).
Yield 90%; yellow solid; mp. 221–224∘C; IR (KBr, cm−1): 1729
(lactone C=O), 3450 (OH); 1HNMR (300MHz, DMSO-𝑑
6
):
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𝛿 2.42 (s, 3H, 6-CH
3
), 6.93 (s, 1H, C
3
–H), 7.23–8.48 (m, 7H,
Ar–H), 11.42 (s, 1H,OH,D
2
Oexchangeable) ppm;Anal. Cald.
for C
18
H
12
O
4
: C, 73.97; H, 4.14. Found: C, 73.89; H, 4.07.
4-(3-Hydroxy-benzofuran-2-yl)-7-methyl-chromen-2-one (3b).
Yield 93%; yellow solid; mp. 229–232∘C; IR (KBr, cm−1): 1730
(lactone C=O), 3440 (OH); 1HNMR (300MHz, DMSO-𝑑
6
):
𝛿 2.43 (s, 3H, 7-CH
3
), 6.91 (s, 1H, C
3
–H), 7.21–8.42 (m, 7H,
Ar–H), 11.22 (s, 1H, OH) ppm; Anal. Cald. for C
18
H
12
O
4
: C,
73.97; H, 4.14. Found: C, 73.89; H, 4.08.
4-(3-Hydroxy-benzofuran-2-yl)-6-chloro-chromen-2-one (3c).
Yield 86%; yellow solid; mp. 260–263∘C; IR (KBr, cm−1): 1743
(lactone C=O), 3460 (OH); 1HNMR (300MHz, DMSO-𝑑
6
):
𝛿 7.04 (s, 1H, C
3
–H), 7.34–8.61 (m, 7H, Ar–H), 11.66 (s, 1H,
OH) ppm; Anal. Cald. for C
17
H
9
ClO
4
: C, 65.30; H, 2.90.
Found: C, 65.19; H, 2.81.
4-(3-Hydroxy-benzofuran-2-yl)-6-bromo-chromen-2-one (3d).
Yield 90%; yellow solid; mp. 247–250∘C; IR (KBr, cm−1):
1736 (lactone C=O), 3435 (OH); 1HNMR (300MHz, DMSO-
𝑑
6
): 𝛿 7.00 (s, 1H, C
3
–H), 7.35–8.70 (m, 7H, Ar–H), 11.65 (s,
1H, OH) ppm; Anal. Cald. for C
17
H
9
BrO
4
: C, 57.14; H, 2.54.
Found: C, 57.02; H, 2.41.
4-(3-Hydroxy-benzofuran-2-yl)-6-flouro-chromen-2-one (3e).
Yield 84%; yellow solid; mp. 242–244∘C; IR (KBr, cm−1):
1723 (lactone C=O), 3456 (OH); 1HNMR (300MHz, DMSO-
𝑑
6
): 𝛿 7.06 (s, 1H, C
3
–H), 7.35–8.63 (m, 7H, Ar–H), 11.70 (s,
1H, OH) ppm; Anal. Cald. for C
17
H
9
FO
4
: C, 68.92; H, 3.06.
Found: C, 68.80; H, 2.93.
4-(3-Hydroxy-benzofuran-2-yl)-5,6-benzo-chromen-2-one (3f ).
Yield 89%; yellow solid; mp. 222–225∘C; IR (KBr, cm−1): 1725
(lactone C=O), 3409 (OH); 1HNMR (300MHz, DMSO-𝑑
6
):
𝛿 6.99 (s, 1H, C
3
–H), 7.25–9.30 (m, 10H, Ar–H); 11.5 (s, 1H,
OH) ppm;Anal. Cald. forC
21
H
12
O
4
: C, 76.82;H, 3.68. Found:
C, 76.70; H, 3.54.
4-(3-Hydroxy-benzofuran-2-yl)-6,8-dimethyl-chromen-2-one
(3g). Yield 91%; colorless solid; mp. 228–231∘C; IR (KBr,
cm−1): 1719 (lactone C=O), 3416 (OH); 1H NMR (300MHz,
DMSO-𝑑
6
): 𝛿 2.35 (d, 6H, 6,8-dimethyl), 6.92 (s, 1H, C
3
–H),
7.30–8.15 (m, 6H, Ar–H), 10.45 (s, 1H, OH) ppm; LC-MS: 307
[M + H]; Anal. Cald. for C
20
H
18
O
5
: C, 71.41; H, 5.36. Found:
C, 71.28; H, 5.24.
4-(3-Hydroxy-benzofuran-2-yl)-6-isopropyl-chromen-2-one
(3h). Yield 93%; yellow solid; mp. 209–211∘C; IR (KBr, cm−1):
1714 (lactone C=O), 3428 (OH); 1HNMR (300MHz, DMSO-
𝑑
6
): 𝛿 1.26 (d, 6H, 2-CH
3
of isopropyl), 3.00 (m, 1H, CH of
isopropyl), 6.93 (s, 1H, C
3
–H), 7.33–8.42 (m, 7H, Ar–H), 11.41
(s, 1H, OH) ppm; 13C NMR (400MHz, DMSO-𝑑
6
): 𝛿 24.5,
32.3, 110.2, 111.9, 112.8, 117.5, 121.8, 125.6, 126.1, 127.4, 128.1,
129.3, 131.7, 145.2, 148.3, 157.6, 158.8, 158.6, 160.1 ppm; Anal.
Cald. for C
20
H
16
O
4
: C, 74.99; H, 5.03. Found: C, 74.88; H,
4.92.
4-(3-Hydroxy-benzofuran-2-yl)-6-tert-butyl-chromen-2-one
(3i). Yield 93%; yellow solid; mp. 214–216∘C; IR (KBr,
cm−1): 1710 (lactone C=O), 3432 (OH); 1H NMR (300MHz,
DMSO-𝑑
6
): 𝛿 1.37 (s, 9H, tert-butyl), 6.86 (s, 1H, C
3
–H),
6.92–8.58 (m, 7H, Ar–H), 11.42 (s, 1H, OH) ppm; Anal. Cald.
for C
21
H
18
O
4
: C, 75.43; H, 5.03. Found: C, 75.32; H, 4.90.
4-(3-Hydroxy-benzofuran-2-yl)-6-benzyl-chromen-2-one (3j).
Yield 96%; yellow solid; mp. 224–227∘C; IR (KBr, cm−1): 1717
(lactone C=O), 3422 (OH); 1H NMR (300MHz, DMSO-𝑑
6
):
𝛿 4.07 (s, 2H, C
6
–CH
2
), 6.96 (s, 1H, C
3
–H), 7.07–8.39 (m, 12H,
Ar–H), 11.49 (s, 1H, OH) ppm; Anal. Cald. for C
24
H
16
O
4
: C,
78.25; H, 4.38. Found: C, 78.12; H, 4.26.
4-(3-Hydroxy-benzofuran-2-yl)-6-methoxy-chromen-2-one (3k).
Yield 95%; yellow solid; mp. 220–222∘C; IR (KBr, cm−1): 1718
(lactone C=O), 3424 (OH); 1HNMR (300MHz, DMSO-𝑑
6
):
𝛿 3.81 (s, 3H, 6-OCH
3
), 6.99 (s, 1H, C
3
–H), 7.28–8.10 (m, 7H,
Ar–H), 11.49 (s, 1H, OH) ppm; Anal. Cald. for C
18
H
12
O
5
: C,
70.13; H, 3.92. Found: C, 70.01; H, 3.81.
7. Conclusion
All the tested compounds (2b-k) and (3a-k) were shown to
exhibit better activity against Staphylococcus aureus than the
standard Ciprofloxacin. The compound (3k) (R = 6-OMe)
was found to be more potent cytotoxic than the standard 5-
fluorouracil.
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